Literature DB >> 20090405

The porphyrias: clinic, diagnostics, novel investigative tools and evolving molecular therapeutic strategies.

A-M van Tuyll van Serooskerken1, P Poblete-Gutiérrez, J Frank.   

Abstract

The porphyrias are clinically and genetically heterogeneous metabolic disorders resulting from a predominantly hereditary dysfunction of specific enzymes involved in heme biosynthesis. Today, the clinical, biochemical, and genetic characteristics of this fascinating group of diseases are well established. Recently, different in vitro and animal models have facilitated the investigation of etiopathologic mechanisms in the different types of porphyria and the development of causal treatment strategies such as pathway interference, enzyme replacement, and gene therapy. The continuous progress in basic science has made an invaluable contribution to the rapid translation of discoveries made in the laboratory into new diagnostics and therapeutics in the near future. 2010 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20090405     DOI: 10.1159/000257260

Source DB:  PubMed          Journal:  Skin Pharmacol Physiol        ISSN: 1660-5527            Impact factor:   3.479


  1 in total

Review 1.  [Congenital erythropoietic porphyria : An update].

Authors:  C Wenner; N J Neumann; J Frank
Journal:  Hautarzt       Date:  2016-03       Impact factor: 0.751

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.